This case report illustrates how the benefits of FMT may apply to AD in a very meaningful way and quickly. The 82 year old patient had C. diff, which made them eligible for FMT and they also had AD which was greatly improved after the FMT was administered. Considering the established safety profile of FMT and the fact that if the FDA would approve it for AD, it could be available in as little as two or three years to the masses of AD patients who desperately need a working remedy that can potentially improve their condition as discussed in this link to a case report :
journals.sagepub.com/doi/ep...
Here is a very relevant quote from the case report :
' An 82-year-old man presented for opinion and management of recurrent CDI following hospitalization for methicillin-resistant Staphylococcus aureus pneumonia. The patient had previously failed several courses of antibiotics for CDI, including vancomycin, vancomycin with metronidazole, fidaxomicin, and bezlotoxumab, with relapse confirmed via symptom recurrence and positive stool test.
At the time of presentation, the patient was under the care of his primary care physician and his neurologist for the treatment of AD, following a gradual 5-year decline in memory and cognition. The patient was taking memantine (28 mg once daily) and donepezil (23 mg once daily). The patient’s dementia symptoms included confusion, memory loss, depression, and flattened affect. On his most recent Mini-Mental State Examination (MMSE) administered by the neurologist, the patient scored 20, indicating mild cognitive impairment. This result reflected the gastroenterologist’s findings and was within the expected range for patients with AD. The patient’s wife reported that he no longer appeared to enjoy socializing, and required considerable assistance with basic tasks such as food preparation, bathing, and taking his medication. Neuropsychiatric testing revealed significant impairments in the areas of memory and semantic language abilities, nonverbal learning, and divided attention and response inhibition. His scores in these areas were within the first through fifth percentiles for function.
Following a detailed discussion regarding the potential risks and benefits associated with the procedure, the patient underwent a single 300 mL FMT infusion (per the Borody method)15 using stool from the patient’s 85-year-old wife as a donor. The patient’s wife was intellectually acute, with normal affect and stable mood. Following the procedure, the patient’s CDI symptoms resolved, and repeat stool testing 2 months later was negative.
At the follow-up visit 2 months post-FMT, the patient’s wife reported improvements in the patient’s mental acuity and affect. The MMSE was re-administered by the gastroenterologist (and subsequently by the neurologist) and the patient scored 26, indicating normal cognition. Four months post-FMT, the patient reported continued improvement in memory, with no progression in symptoms. The patient now remembered his daughter’s birthday, which he had not been able to recall previously, and was able to correct the physician’s recollections of his symptoms. Six months post-FMT, the patient reported a marked improvement in mood, was more interactive, and showed more expressive affect. Readministration of the MMSE revealed that the patient’s score had further increased to 29.
Because no study was conducted, no ethics approval or consent was required. Verbal consent was obtained from the patient for the publication of the report; however, this was merely a courtesy because all data have been de-identified.
Will the government allow such alternative uses of FMT for people with dementia or continue to let them waste away in front of their families, friends and caregivers using the currently ineffective drug options that the government has approved for AD or dementia? What patient with dementia, who is still cognizant enough to understand the potential of FMT for AD, would not want to try FMT?
Art
Experience with B5 supplementation?
does anyone use pepto-bismol?
